Updated Guideline Introduces Recommendations for Prevention & Treatment of Glucocorticoid-Induced Osteoporosis
The Rheumatologist reports the American College of Rheumatology (ACR) released a summary of its updated guideline for the prevention and treatment of glucocorticoid-induced osteoporosis in September. The guideline includes recommendations on abaloparatide and romosozumab, which are two medications that are newly available since the 2017 guideline, as well as recommendations for other osteoporosis medications.
The guideline also recommends sequential therapy (any treatment regimen in which the patient is given one treatment followed by another), which was not addressed in the previous guideline. The recommendations for sequential therapies are based in part on some study designs, long-term follow-up studies, and new clinical trials.
“Some physicians may be surprised about the need for sequential therapy when completing a course of denosumab, parathyroid hormone/parathyroid hormone related protein, or romosozumab. If not done, patients could be at risk of rapidly developing vertebral fractures and bone loss,” said Linda A. Russell, MD, rheumatologist and director of perioperative medicine and the Osteoporosis and Metabolic Bone Health Center at HSS and co-principal investigator of the guideline.
Furthermore, the updated guideline also gives more flexibility on drug selection and considers patient and physician preferences.
Read the full article at the-rheumatologist.org.
Additional coverage: Medscape.com.